FDA advisers back Lundbeck and Otsuka's Rexulti in Alzheimer's disease agitation

In a 9-1 vote on Friday, experts on the FDA's Psychopharmacologic Drugs Advisory Committee and the Peripheral and Central Nervous System Drugs Advisory Committee recommended a favorable benefit-risk profile for the proposed Rexulti use.